Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
Authors: Hope S. Rugo, Olufunmilayo I. Olopade, Angela DeMichele, Christina Yau, Laura J. van ’t Veer, Meredith B. Buxton, Michael Hogarth, Nola M. Hylton, Melissa Paoloni, Jane Perlmutter, W. Fraser Symmans, Douglas Yee, A. Jo Chien, Anne M. Wallace, Henry G. Kaplan, Judy C. Boughey, Tufia C. Haddad, Kathy S. Albain, Minetta C. Liu, Claudine Isaacs, Qamar J. Khan, Julie E. Lang, Rebecca K. Viscusi, Lajos Pusztai, Stacy L. Moulder, Stephen Y. Chui, Kathleen A. Kemmer, Anthony D. Elias, Kirsten K. Edmiston, David M. Euhus, Barbara B. Haley, Rita Nanda, Donald W. Northfelt, Debasish Tripathy, William C. Wood, Cheryl Ewing, Richard Schwab, Julia Lyandres, Sarah E. Davis, Gillian L. Hirst, Ashish Sanil, Donald A. Berry, Laura J. Esserman
Journal: New England Journal of Medicine (2016)

The genetic and clinical heterogeneity of breast cancer makes the identification of effective therapies challenging. We designed I-SPY 2, a phase 2, multicenter, adaptively randomized trial to screen multiple experimental regimens in combination with standard neoadjuvant chemotherapy for breast cancer. The goal is to match experimental regimens with responding cancer subtypes. We report results for veliparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, combined with carboplatin.In this ongoing trial, women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter; cancers are categorized into eight biomarker subtypes on the basis of status with regard to human epidermal growth factor receptor 2 (HER2), hormone receptors, and a 70-gene assay. Patients undergo adaptive randomization within each biomarker subtype to receive regimens that have better performance than the standard therapy. Regimens are evaluated within 10 biomarker signatures (i.e., prospectively defined combinations of biomarker subtypes). Veliparib-carboplatin plus standard therapy was considered for HER2-negative tumors and was therefore evaluated in 3 signatures. The primary end point is pathological complete response. Tumor volume changes measured by magnetic resonance imaging during treatment are used to predict whether a patient will have a pathological complete response. Regimens move on from phase 2 if and when they have a high Bayesian predictive probability of success in a subsequent phase 3 neoadjuvant trial within the biomarker signature in which they performed well.With regard to triple-negative breast cancer, veliparib-carboplatin had an 88% predicted probability of success in a phase 3 trial. A total of 72 patients were randomly assigned to receive veliparib-carboplatin, and 44 patients were concurrently assigned to receive control therapy; at the completion of chemotherapy, the estimated rates of pathological complete response in the triple-negative population were 51% (95% Bayesian probability interval [PI], 36 to 66%) in the veliparib-carboplatin group versus 26% (95% PI, 9 to 43%) in the control group. The toxicity of veliparib-carboplatin was greater than that of the control.The process used in our trial showed that veliparib-carboplatin added to standard therapy resulted in higher rates of pathological complete response than standard therapy alone specifically in triple-negative breast cancer. (Funded by the QuantumLeap Healthcare Collaborative and others; I-SPY 2 TRIAL ClinicalTrials.gov number, NCT01042379.).